Literature DB >> 8890219

Pneumocystis carinii pneumonia in scid mice induced by viable organisms propagated in vitro.

J M Beck1, R L Newbury, B E Palmer.   

Abstract

Pneumocystis carinii pneumonia remains a major cause of morbidity and mortality in human immunodeficiency virus-infected individuals, despite the widespread use of prophylaxis and the development of new chemotherapeutic agents. The study of P. carinii and of pulmonary host defenses directed against it has been limited by lack of reliable, reproducible methods to obtain pure populations of organisms in useful quantities. While recent success has been achieved with cultures of rat P. carinii organisms, cultures of mouse P. carinii organisms have not been successful. Experiments were performed to determine whether P. carinii organisms derived from mice could be propagated in vitro. Mouse P. carinii organisms, obtained from the lungs of chronically infected athymic mice, were inoculated into spinner flasks containing HEL299 feeder cells seated on microcarrier beads. The numbers of mouse P. carinii organisms increased significantly over 7 days in culture. To test the viability and pathogenicity of these cultured organisms, P. carinii organisms were harvested after 7 days of culture and were inoculated intratracheally into susceptible scid mice. Four weeks after inoculation, scid mice developed uniformly severe P. carinii pneumonia. These studies demonstrate for the first time that mouse P. carinii organisms can be propagated in vitro. Furthermore, cultured mouse P. carinii organisms maintain their pathogenicity in an in vivo model system. This culture system will have important applications in the study of P. carinii biology and in the study of host defenses directed against this important opportunistic pathogen.

Entities:  

Mesh:

Year:  1996        PMID: 8890219      PMCID: PMC174425          DOI: 10.1128/iai.64.11.4643-4647.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

Review 1.  Prevention and treatment of pneumocystis pneumonia.

Authors:  H Masur
Journal:  N Engl J Med       Date:  1992-12-24       Impact factor: 91.245

2.  Propagation of Pneumocystis carinii in vitro.

Authors:  L L Pifer; W T Hughes; M J Murphy
Journal:  Pediatr Res       Date:  1977-04       Impact factor: 3.756

3.  Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes.

Authors:  J M Beck; M L Warnock; J L Curtis; M J Sniezek; S M Arraj-Peffer; H B Kaltreider; J E Shellito
Journal:  Am J Respir Cell Mol Biol       Date:  1991-08       Impact factor: 6.914

4.  Growth and metabolism of Pneumocystis carinii in axenic culture.

Authors:  M T Cushion; D Ebbets
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

5.  A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.

Authors:  J Shellito; V V Suzara; W Blumenfeld; J M Beck; H J Steger; T H Ermak
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment.

Authors:  A H Limper; W J Martin
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

7.  Host species-specific antigenic variation of a mannosylated surface glycoprotein of Pneumocystis carinii.

Authors:  F Gigliotti
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

8.  Fatty acid composition of the major phospholipids of Pneumocystic carinii: comparison with those in the lungs of normal and methylprednisolone-immunosuppressed rats.

Authors:  Z Guo; D H Beach; E S Kaneshiro
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

Review 9.  A fifteen-year perspective on the in vitro culture of Pneumocystis carinii.

Authors:  L L Pifer
Journal:  J Protozool       Date:  1989 Jan-Feb

10.  Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice.

Authors:  A G Harmsen; M Stankiewicz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  1 in total

1.  Pneumocystis jirovecii Rtt109, a novel drug target for Pneumocystis pneumonia in immunosuppressed humans.

Authors:  Jayme L Dahlin; Theodore Kottom; Junhong Han; Hui Zhou; Michael A Walters; Zhiguo Zhang; Andrew H Limper
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.